학술논문
143P Quality of life (QoL) with palbociclib (PAL) plus endocrine therapy (ET) versus (vs) capecitabine (CAP) in luminal metastatic breast cancer (MBC) patients (pts) in the PEARL study
Document Type
Abstract
Author
Source
In Annals of Oncology May 2020 31 Supplement 2:S66-S67
Subject
Language
ISSN
0923-7534